Podcasts about wegovy

“It's kind of a miracle, frankly,” says Dr. John Buse, a distinguished professor at the University of North Carolina School of Medicine, referring to the effectiveness of GLP-1 receptor agonist medications such as Ozempic in treating type 2 diabetes, promoting significant weight loss, and reducing cardiovascular risk. As a physician scientist for the last three decades at UNC, Dr. Buse has played a key role in ushering in this new era of diabetes care, leading or participating in over 200 clinical studies on this class of drugs and others. “Nothing has impacted diabetes care like the GLP-1 receptor agonists. I have lots of patients whose diabetes was never well controlled who have seen all their metabolic problems essentially resolved.”  In this fascinating conversation with Raise the Line host Lindsey Smith, Dr. Buse not only explains how these drugs work, but also provides a clear-eyed look at side effects, and addresses issues of cost and access. Join us for the remarkable story – including the role played by Gila monsters -- behind one of the biggest developments in medicine over the past several years from a world renowned diabetes researcher and clinician. Mentioned in this episode:UNC School of Medicine If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

In part 2 of this GLP-1 series, Ted shares two real-life case studies that reveal when weight loss drugs like Ozempic, Wegovy, and Mounjaro deliver results—and when they don't. Discover the surprising lessons that make the difference. If you missed part 1, go back to hear Ted break down the dos and don'ts of these drugs, how they work, the results people are seeing, and the lifestyle shifts that ensure lasting success. Listen now!  Click here for part 1:   

Millions of adults take popular drugs like Ozempic, Wegovy, and Mounjaro to treat chronic conditions and/or lose weight. The GLP-1 medications have made headlines for their effectiveness, and new studies have shown that some of them can also curb alcohol and drug consumption and lower the risk of a heart attack. But not everyone has equal access to the medications. While some patients are able to obtain them through their health care providers, others have turned to online platforms that don't require prescriptions. In many cases, they can also be cost prohibitive: Ozempic, for example, can cost up to $1,000 per month without insurance. This hour, we explore the latest with these medications: what they treat, how they work, and who should be able to access them. Our guests: Zachary Burns, D.O., assistant professor of family medicine at the University of Rochester Medical Center and associate director of Moving Medicine Forward  Erica Davis, patient who uses weight loss medication, theater professional, educator, and mother Molly Ranney, MS, RD, CDN, CSOWM, lead dietitian for the Bariatric Center at Highland Hospital Kaci Schiavone, M.D., assistant professor in the Department of Surgery, Bariatric/GI at the University of Rochester Medical Center ---Connections is supported by listeners like you. Head to our donation page to become a WXXI member today, support the show, and help us close the gap created by the rescission of federal funding.---Connections airs every weekday from noon-2 p.m. Join the conversation with questions or comments by phone at 1-844-295-TALK (8255) or 585-263-9994, email, Facebook or Twitter. Connections is also livestreamed on the WXXI News YouTube channel each day. You can watch live or access previous episodes here.---Do you have a story that needs to be shared? Pitch your story to Connections.

Named one of New Zealand's Top Women in Food & Drink, Ashley Wilson provides her take on the 2025 International Congress of Nutrition (ICN) in Paris. We cover: 6:40 The power of connecting 9.00 Ultra-Processed Food Heated Debate12:15 Restructure Trial - Meal Texture/Eating Rate13:30 AI Digital Marketing 17:10 Sweet Tooth Trial - our taste for sweetness 20:00 What the media shows us vs the scientific evidence22:30 Jo Wicks “killer bar” PR vs Eat Lancet25:30 UN High Level Meeting & non-communicable diseases 27:20 GLP-1 & Wegovy released in NZ28:35 Heston Blumenthal, celebrity chef - Scaling down tasting menu 30:10 Wrap up One-liners you don't want to miss:"We have just had the release of EAT- Lancet 2 which is this global report on planetary health and recommendations on how we should be eating. They have a huge communication campaign in place, however at their launch only half of the badges for the media have been picked up. We are seeing hardly any global media - just a handful of articles on the launch. In comparison, Jo Wicks is getting all of the media. It is really important we are looking to not just the media but other sources of information such as research or our dietitians - our leads in the profession, for this information, not just this the media. Because it can be really one-sided and can be related to click-bait - what's going to get the readership.”Ashley's Top LinkedIn Follows:Ellie Hadjilucas - Founder of Nutricomms, Carrie Ruxton - PhD, Marcia Terra - IUFoST. Support the show

Send us a textThis week, I'm joined by Dr. Betsy Greenleaf, board-certified female urogynecologist and women's health expert. We talk about menopause, perimenopause, weight gain, the new weight loss drugs, HRT (hormone replacement therapy), pelvic health, and vaginal wellness. Betsy explains how to stay strong, confident, and comfortable in midlife, the difference between natural and synthetic hormones, and how to make HRT work for you. We also cover weight-loss drugs like Ozempic, Mounjaro, and Wegovy, why they're not a long-term solution, and the importance of muscle, stress reduction, and nutrition for midlife wellness.Plus, Betsy shares her top tips for pelvic health, including Kegels, topical oestrogen, red-light therapy, probiotics, and boric acid resets, and her golden rule for midlife self-care: give yourself grace.It's an honest, empowering and incredibly informative conversation we all need to hear.Linkshttps://buymeacoffee.com/amandaryderBetsy's Pelvic Floor Store that she mentionedJust by clicking on the link you will receive 10% off Betsy's productsThe Pelvic Floor Store:  https://pelvicfloorstore.com/discount/BETSYGREENLEAFSTORE  https://pauseinstitute.comhttps://www.instagram.com/drbetsygreenleafAmanda Ryder Registered Nutritional Therapist ~ Author of Feel good for Menopause @amandarydernutritionhello@amandaryder.co.ukwww.amandaryder.co.uk

In this comeback episode of Cacao with Kezia, I unpack what the research says about GLP-1 weight-loss drugs (Ozempic/Wegovy/Mounjaro): why most people regain about two-thirds of the weight after stopping, the key risks (gallbladder, gastroparesis, pancreatitis, bone and nutrient concerns), and the four foundations that make results stick,insulin management, sleep & stress, protein & fibre, and understanding your unique root causes. Compassionate, practical, evidence-informed - and no judgement. Work with me: Book a ROOT session to identify your personal drivers and plan a sustainable strategy → keziahall.com/root Free yoga series: GROUNDED (6-week, online, donation-based, starting 29th October) → join the series here (hop in at any point)  

What if everything you thought GLP-1s were for—was just the beginning? I sit down with Dr. Rocio Salas-Whalen, a board-certified endocrinologist and obesity medicine specialist with over 15 years of experience prescribing GLP-1s, to explore what these medications are really doing in the body. Whether you're already taking Ozempic or Wegovy, considering starting, or just curious, this conversation will change how you think about metabolism, hormones, and health. Dr. Salas-Whalen explains how GLP-1s go far beyond appetite suppression and weight loss—they can impact fertility, inflammation, autoimmune conditions, and even how your brain responds to addictive cravings and stress. You'll also hear how body composition, not BMI, is the future of metabolic health, and what to ask your doctor before starting GLP-1s.

Send us a textDr. Acosta returns to Causes or Cures to talk about the next big leap in obesity research: using genetics and machine learning to predict which patients will get side effects to popular GLP-1 weight-loss medications like Wegovy and Zepbound. Previously, he was on Causes or Cures to discuss your individual obesity type. He and his team are uncovering why some people experience major weight loss while others face tough side effects—especially nausea. The goal? True precision medicine for obesity: matching the right treatment to the right person before treatment even begins. (You can learn more about their available tests and company here.) Topics We DiscussDr. Acosta's background and what drew him to obesity researchWhy not all obesity is the same—and why that matters for patients and doctorsThe most common questions patients ask about GLP-1 drugs like Wegovy and ZepboundHow big a problem side effects like nausea really are in practiceNew research using genetic markers to predict who's more likely to experience side effectsWhether eating style affects nausea and how Dr. Acosta coaches patients on nutrition while using these medicationsThe possibility of genetic testing before prescribing GLP-1sWhat we know about rarer side effects, from vision to hearing changes, if he thinks more side effects will emergeWhat “satiation” (feeling full) means and why it varies so much between peopleHow genetic risk and satiation scores could determine which obesity treatment works bestDr. Acosta's thoughts on obesity prevention, especially on renewed energy to take on the unhealthy food industryThe persistence of stigma—why “willpower” doesn't tell the whole storyWhether the current obsession with obesity drugs distracts from prevention, nutrition, and community health Listen if you've ever wondered:Why GLP-1 drugs don't work the same for everyoneWhat your genes have to do with weight loss, feeling full and side effectsHow soon doctors could use genetic tests to personalize obesity treatmentWhether prevention is being overshadowed by the pharma spotlightWhy it mattersObesity isn't a one-size-fits-all condition—and neither should its treatment be. Dr. Acosta's research could mark a turning point in how we approach weight loss: scientifically, compassionately, and individually. Dr. Acosta is a Consultant of Gastroenterology and Hepatology at the Mayo Clinic, as well as an Associate Professor of Medicine. His research focus is on gastrointestinal physiology and the complexity of food intake regulation as it relates to obesity. You can learn more about his work here.You can contact Dr. Eeks at bloomingwellness.com.Follow Eeks on Instagram here.Or Facebook here.Or X.On Youtube.Or TikTok.SUBSCRIBE to her WEEKLY newsletter here! (Now featuring interviews with top experts on health you care about!)Support the show

Weight-loss drugs like Ozempic®, Wegovy®, and Mounjaro™  or GLP-1 can reset your appetite—but only you can rewire your brain. In this episode, I'm showing you how to use your quiet-appetite season on Ozempic as a bridge, not a crutch. You'll learn how to shift from the Dieter's Mindset to the Stop Dieting Forever Mindset and build habits that actually stick while your food noise is quiet. ✨ What You'll Learn in This Episode: Why Ozempic can change your biology—but not your beliefs How to reprogram habits while your appetite is quiet The difference between the Dieter's Mindset and the Stop Dieting Forever Mindset How to apply the Four ForeverWell Essentials  A guilt-free way to enjoy treats—with grown-woman boundaries How to use self-coaching to manage stress and cravings The TikTok story that shows what happens when you skip the mindset work ====================== FEATURED ON THE SHOW / RESOURCES

Maigrir rapidement. C'est la promesse de nombreux influenceurs faisant la promotion du Wegovy ou de l'Ozempic sur les réseaux sociaux. Ces médicaments, à destination des obèses et des diabétiques, sont utilisés par des personnes non malades pour perdre du poids de façon spectaculaire. A l'ère du “Skinny Tok”, cette tendance qui fait l'apologie de la maigreur sur TikTok, ces traitements “miracle” jouissent d'une grande publicité. Certains font tout pour se les procurer créant des pénuries pour les personnes diabétiquesEffets secondaires, médicaments frauduleux, mauvaise utilisation du traitement … Maigrir à tout prix n'est pas sans danger. Code source décortique le phénomène derrière ces médicaments minceurs avec Nicolas Berrod, journaliste spécialiste des sujets de santé au Parisien. Crédits. Direction de la rédaction : Pierre Chausse - Rédacteur en chef : Jules Lavie - Reporter : Barbara Gouy - Production : Thibault Lambert, Pénélope Gualchierotti et Anaïs Godard - Réalisation et mixage : Julien Montcouquiol - Musiques : François Clos, Audio Network - Archives : TikTok. Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.

Am Major board shake-up at Wegovy maker Novo Nordisk. How that leadership change impacts a stock that is down 50% in a year. Then Alphabet shares fall on fears of OpenAI competition in the form of a web browser. And Philip Morris down big despite an earnings beat. The CEO joins to break down the quarter. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

According to a KFF poll, about one in eight, or 12%, of adults in the United States have used a GLP-1 medicine like Ozempic, Trulicity, Victoza, Mounjaro, Wegovy, or Zepbound. These drugs were originally developed to treat diabetes, but quickly started being prescribed for weight loss and other uses. While they seem like wonder drugs, GLP-1 medicines do cause side effects and have risks. Nausea, vomiting, diarrhea, and constipation are common side effects. The drugs also can cause dizziness, headaches, and elevated heartbeat.  Dr. Neil Iyengar is a breast medical oncologist who studies how diet and exercise can improve quality of life for people with breast cancer. He's also prescribed GLP-1 medicines for the people he cares for. Listen to the episode to hear Dr. Iyengar explain: how GLP-1 medicines work the risks these drugs may pose for people receiving chemotherapy, immunotherapy, or a CDK4/6 inhibitor why he works closely with a weight loss specialist or endocrinologist when prescribing these medicines why the medicines work best when a person also makes lifestyle changes

Prispres fortsætter på Novo og kan betyde halvering af prisen på Wegovy. 14 danske banker har udstedt 200.000 ulovlige dankort. Jesper Rangvid spår at den danske stats formue vil vokse meget kraftigt. Kursen på 3,5-procentslånet nærmer sig 98. LA forslår to danske atomkraftværker. Vært: Lasse Ladefoged (lasse.ladefoged@borsen.dk)

Are Ozempic, Wegovy, and Mounjaro really the miracle solution for weight loss? In part 1 of this 2 part series, Ted breaks down how GLP-1 drugs work, the results people are seeing and the potential downsides no one talks about. Plus, the lifestyle shifts that ensure lasting success. Listen now! 

This is a free preview of a paid episode. To hear more, visit abbieattwoodwellness.substack.comRagen Chastain is back to continue our conversation about weight, health, and diet culture — this time answering listener questions about the GLP-1s you've been hearing so much about: Wegovy, Ozempic, and other weight-loss drugs.Following up on last week's episode, Ragen helps us separate hype from reality. We dive into how these drugs actually work — and don't — their risks and side effects, and the broader context around the pharmaceutical industry and public discourse on weight.In this episode, we cover:What GLP-1s actually are and how they function in the bodyThe side effects and potential health risks of these drugsHow effective they really are for long-term weight managementWhat happens when weight loss plateaus while taking themThe impact of pharma companies, marketing, and the weight-loss industryThe shortages affecting diabetics who rely on GLP-1s for medical reasonsTune in to get a clear, evidence-based perspective on the weight-loss drug craze, and to continue unpacking the bigger conversation about weight, health, and stigma.Support the show: Enjoying this podcast? Please support the show on Substack for bonus episodes, community engagement, and access to "Ask Abbie" at abbieattwoodwellness.substack.com/subscribe Apply for Abbie's Group Membership:Already been at this anti-diet culture thing for a while, but want community and continued learning? Apply for Abbie's monthly membership: https://www.abbieattwoodwellness.com/circle-monthly-group Social media:Find the show on Instagram: @fullplate.podcastFind Abbie on Instagram: @abbieattwoodwellness Podcast Cover Photography by Anya McInroyPodcast Editing by Brian WaltersThis podcast is ad-free and support comes from your support on Substack. Subscribe HERE.

Claim your complimentary gift of my exclusive mini weight care guide today!Link: Weight Care Guide — Dr. Francavilla Show (thedrfrancavillashow.com)Ever notice how travel can completely throw off your routine—especially when you're on a weight loss plan? Between airports, restaurants, and unpredictable schedules, it can feel like all your progress is at risk the moment you pack your bags.In this episode, we're tackling one of the biggest challenges my patients—and honestly, I—face when it comes to staying consistent: travel. Whether your trip is for work, vacation, or a bit of both, this one's for you.We'll cover:Smart eating while travelingPlanning for balanced meals on the goStaying active during your tripTraveling smoothly with your medicationsWhy you shouldn't change your dose before travelingKeeping your healthy habits going while awayI've learned a lot from my own travels—speaking at conferences, attending events, and doing advocacy work—and I've seen what works for both me and my patients who want to enjoy their trips without losing progress.We'll get into simple, practical strategies to stay consistent with nutrition, movement, medication, and mindset—the four pillars I use in obesity medicine. And as a bonus, I'll share key tips for anyone using Wegovy or Zepbound: how to pack them, store them, and stay on track with dosing while you're away.So if you've got a trip coming up and want to come home feeling good, energized, balanced, and still on track, this episode will walk you through exactly how to make that happen.Connect with me:Instagram: doctorfrancavillaFacebook: Help Your Patients Lose Weight with Dr. FrancavillaWebsite: Dr. Francavilla ShowYoutube: The Doctor Francavilla ShowGLP Strong: glpstrong.com

In this episode Tom tells the Slow Road to Better crew about his experience with Wegovy and his weight loss journey. The crew talks about weight gain, their love of food and how their weight impacts their mood.

In this hot health topic episode of Accelerated Health with Sara Banta, I uncover the latest study revealing the #1 supplement to prevent Ozempic muscle loss!

Medications such as Ozempic and Wegovy are proven to be highly effective for weight management. They are also increasingly being found to treat other conditions and reduce the risk of disease, promising health benefits far beyond the treatment of obesity. But these drugs generally need to be continued for weight loss to be maintained, so there are big questions to be answered about their use and significant challenges to overcome around access and availability. In front of a live audience at Wellcome Collection in London, Claudia and her guests explore the potential and negatives of weight loss injections and ask whether they really are the next wonder drug.

n the News.. COVID-19 & T1D, Ozempic Pill Progress, Faster Insulin, “Beyond Misconceptions,” and More It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: A new study looks at the link between COVID-19 and very young children, Lilly moves ahead with their Ozempic oral pill, ultra-rapid insulin clears another hurdle, Beyond Type 1 launches a new campaign and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX https://www.scientificamerican.com/article/advances-in-type-1-diabetes-science-and-tech/ This article is part of “Innovations In: Type 1 Diabetes,” an editorially independent special report that was produced with financial support from Vertex. XX More evidence linking COVID 19 to type 1 diabetes.. but still exactly why is a mystery. During the COVID-19 pandemic, there was an unexpected increase in the number of cases of type 1 diabetes in Sweden, particularly among children under 5 and young adult men. The infection accelerated the onset of diabetes among children between the ages of 5 and 9. The researchers looked at data from a 17-year period on the incidence of type 1 diabetes among all people under the age of 30 in Sweden. In addition, they compared the risk of developing diabetes among 720,000 individuals with positive COVID-19 tests against a control group of 3.5 million people. The findings are published in the journal Diabetologia. The number of diabetes cases increased by 12% in 2021 and 9% in 2022 compared with previous years. In 2023, the number of cases was back to a normal level. Despite this, the researchers cannot distinguish a clear connection between COVID-19 infection and diabetes, except for children between 5 and 9 years old. They had an increased risk of type 1 diabetes about one month after a COVID-19 infection even though their total risk did not increase. "However, it's clear that the COVID-19 vaccine can be ruled out as a cause of the increase in diabetes cases. The recommendation for the age group where we saw the strongest increase was not to get vaccinated. In addition, other studies on adults have shown that vaccination reduces the risk of developing type 1 diabetes after a COVID infection." https://medicalxpress.com/news/2025-10-diabetes-young-people-pandemic.html XX A new gene therapy approach aimed at protecting people with type 1 diabetes from developing diabetic kidney disease—a serious and common complication of the condition, has shown promising results in a University of Bristol study. Findings from this new study, published in Molecular Therapy, demonstrated a 64% reduction in a damage indicator for kidney disease, paving the way for a potential new treatment. The study, explored the potential of delivering a protein called VEGF-C directly into kidney cells. Previous studies have shown VEGFC could protect against kidney disease as it helps keep blood vessels in the kidney filter healthy, repairing early signs of diabetes-related kidney damage. https://medicalxpress.com/news/2025-10-gene-therapy-kidney-disease-diabetes.html XX The FDA has agreed to consider Afrezza inhaled insulin for children and teens. The company said in August that it submitted a supplemental Biologics License Application (sBLA) for Afrezza in the pediatric population and it's been assigned a decision deadline date of the end of May, 2026. Afrezza first recieved FDA approval for adults (age 18 and up) in June 2014 https://www.drugdeliverybusiness.com/fda-accepts-application-mannkind-inhaled-insulin-kids/ Update on inhaled insulin for kids.. in the open-label, randomized, phase 3 INHALE-1 clinical trial Afrezza demonstrated safe and effective replacement for rapid-acting meal insulin in children with type 1 diabetes (T1D and demonstrates comparable glycemic control to injected rapid-acting insulin. The INHALE-1 clinical trial assessed the safety and efficacy of Afrezza among children and adolescents with T1D, including a total of 230 patients aged 4 to 17 years. Researchers used basal injected insulin and randomly assigned inhaled insulin or rapid-acting analogue for meals, evaluating the change in hemoglobin A1c levels at 26 weeks. After completing 26 weeks of randomly assigned treatment with either Afrezza or rapid-acting insulin injections combined with basal insulin, participants continued receiving the inhaled insulin until week 52 for an extension phase to evaluate the safety and effectiveness of Afrezza with continued use.1,2 https://www.pharmacytimes.com/view/inhaled-insulin-demonstrates-comparable-safety-lung-function-and-efficacy-to-injectable-insulin-in-type-1-diabetes XX Eli Lilly released the results of two new Phase 3 trials of an experimental GLP-1 pill that the company says could become a “foundational treatment” for type 2 diabetes. The Indianapolis-based drugmaker plans to submit global regulatory applications for orforglipron in the treatment of type 2 diabetes next year. The company said it will seek approval of the drug as an obesity medication by the end of 2025. Lilly is trying to build on the success of its Mounjaro/Zepbound franchise by offering patients a pill instead of an injection. But the company is trailing behind rival Novo Nordisk in developing an oral alternative, and data released so far has raised some skepticism among investors. A study released in August showed that orforglipron could help patients lose an average of about 12% of their body weight. Wall Street had been expecting more; Lilly's injectable drug Zepbound produced weight loss of as much as 21%, and Novo Nordisk has achieved 15% weight loss percentages for both oral and injectable versions of its Wegovy medication.   https://www.fiercebiotech.com/biotech/eli-lillys-orforglipron-bests-farxiga-padding-oral-glp-1-case-pair-phase-3-diabetes-wins   XX XX UF Health Cancer Center researchers have found a surprising culprit behind common health problems such as obesity, diabetes and fatty liver disease: silent genetic glitches in the blood system that occur naturally as people age. The findings, published in the Journal of Clinical Investigation, mean that in the future, simple blood tests could be developed to identify people most at risk early on, helping prevent chronic illnesses and cancer through strategies like diet or lifestyle changes. As people age, stem cells in the bone marrow that produce blood cells gradually accumulate mutations in their DNA. Most mutations don't cause any issues, but sometimes blood stem cells with a mutation can start crowding out their peers. Called clonal hematopoiesis, this condition affects about 10% of older people and is associated with an increased risk of blood cancers like leukemia. It's also linked to a higher risk of obesity and diabetes. But the prevailing thinking was that obesity and related conditions promoted blood cell changes, not the other way around. The new study reverses that. The implications could be far-reaching, particularly as obesity has now overtaken smoking as the most significant and preventable risk factor for cancer. The team is studying how the mutations drive disease. Next, they plan to test how drugs like those commonly used to treat diabetes and new popular weight loss drugs might help reverse or prevent diseases caused by blood cell changes. https://medicalxpress.com/news/2025-10-hidden-blood-mutations-obesity-diabetes.html XX A new ultra rapid insulin continues to move forward. A phase 3 clinical trial of BioChaperone Lispro (liss-pro) conducted in China found it safe and effective compared with Humalog along with a significant reduction of the rise of blood glucose after a test meal.     These results complete and confirm the positive outcomes previously obtained with THDB0206 injection in people with Type 2 Diabetes It combines Adocia's proprietary BioChaperone® technology with insulin lispro, the active ingredient in the standard of care, Humalog® (Eli Lilly).   This innovative formulation acts significantly faster https://pharmatimes.com/news/ultra-rapid-insulin-shows-promise-in-phase-3-trial-for-type-1-diabetes/   Poor blood sugar control in adolescent patients with type 1 diabetes (T1D) may be associated with a higher risk of neuropathy in adulthood, according to recent research from the University of Michigan.1 The study included children diagnosed with T1D between 1990-1992 who were recruited into the Cognition and Longitudinal Assessment of Risk Factors over 30 Years cohort study in Australia. Investigators collected HbA1c from medical records, and microvascular complications were assessed through self-reports, clinical screenings, retinal photographs, and urinary albumin-creatinine testing.3   A total of 30 children were recruited from the original cohort with a mean diagnosis age of 2.9 years. After an average of 29.7 years (standard deviation [SD]: 3.9 years), 33% of participants (n = 13) developed neuropathy, 63% (n = 19) developed diabetes-related eye disease, and 10% (n = 3) developed neuropathy.3 Mean HbA1c estimates during adolescence (9% [74.9 mmol/mol]; 95% CI, 8.6-9.3 [70.5-78.1]) were substantially higher than childhood (8.2% [66.1 mmol/mol]; 95% CI, 7.8-8.5 [61.7-69.4]; P

This week, Brent speaks with Dr. John Buse, a leading endocrinologist at the University of North Carolina and one of the world's foremost experts on diabetes and metabolic health. Dr. Buse unpacks the science behind GLP-1 agonists like Ozempic and Wegovy. He explains their powerful benefits for obesity, diabetes, and heart disease, along with the real risks. Drawing on his decades of research and personal experience using the drugs himself, Dr. Buse offers a grounded, evidence-based look at the promise and pitfalls of GLP-1s for both treatment and longevity. The conversation also touches on the future of microdosing, pharma ethics, and why true preventive care remains medicine's biggest challenge. He's a wonderful guest, hope you enjoy.

This week we're diving into one of the biggest health conversations of the year as we explore GLP 1 weight loss drugs. From Ozempic to Wegovy these medications have changed how we think about food, weight and willpower but they've also raised big questions about what healthy really means. Dr Jack Mosley joins us to unpack the science behind these drugs, the truth about food noise, muscle loss and long term side effects, and what happens when you stop taking them. We also look at natural ways to support GLP 1 function through diet and lifestyle. As these drugs become more accessible and more widely marketed are they a genuine breakthrough or another quick fix in disguise Learn more about your ad choices. Visit podcastchoices.com/adchoices

Losing weight is hard. That's probably why almost three-fourths of American adults are overweight or obese. On this episode, we speak with a distinguished doctor and former FDA commissioner who has personal experience struggling with the scale. In this discussion of popular weight-loss drugs like Wegovy, we tackle the biology of weight. We also interview […]

GLP-1s (like Ozempic and Wegovy) are being called the biggest breakthrough in modern weight loss… But are they really a miracle for women in midlife — or could they turn out to be a major mistake? In today's brand-new podcast episode, we're cutting through the hype and asking the hard questions with a much-loved guest and FDN practitioner, Jennifer Woodward.   Want to watch this episode on YouTube? Click here. Subscribe if you'd like to catch all new episodes live and participate with our guests directly.   Want to learn more about becoming an FDN? Go to fdntraining.com/resources to get our best free workshops and mini-courses! Where to find Jennifer Woodward: Website: jenniferwoodwardnutrition.com Instagram: @jenniferwoodwardnutrition Facebook: @jenniferwoodwardFDNP  

Howie and Harlan are joined by Rajlakshmi Krishnamurthy, the Yale School of Medicine's associate dean for population health, to discuss her work building holistic systems for care at multiple institutions. Harlan discusses healthcare headlines including the launch of "TrumpRX"; Howie reports on a new study taking a novel approach to understanding the impact of the COVID-19 vaccine. Links: Healthcare Headlines “The Latest: Gaza ceasefire holds as Israeli military says Red Cross to transfer remains of deceased” “More than 20 kids in India have died from contaminated cough syrup. Who's to blame?” “Senate-passed BIOSECURE Act would add arrow to Trump's drug-pricing quiver” Wuxi Biologics H.R.8333: BIOSECURE Act TrumpRx “Trump unveils deal for AstraZeneca to cut Medicaid drug prices and join ‘TrumpRx' site” “President announces TrumpRx website for drugs, and pricing deal with Pfizer” “Exclusive: Bill Gates, PAHO consider ways to bring weight-loss drugs to lower-income countries” Pan American Health Organization World Health Organization: Obesity and overweight “Exclusive: Most patients using weight-loss drugs like Wegovy stop within a year, data show” “In biotech, Boston reigns supreme, but its competitive edge is being challenged in new ways” “'Disheartening? Yes. Surprising? No.' Report on the future of biotech in Mass. gives a grim outlook.” Population Health CDC: Patient-Centered Medical Home (PCMH) Model American Academy of Family Physicians: Transitional Care Management “The University of Chicago Medicine to Join CMS Alternative Payment Model” UChicago Medicine: Accountable Care Organization Chicago Health Atlas: Social Vulnerability Index “Relationship Between Social Risk Factors and Emergency Department Use: National Health Interview Survey 2016–2018” The COVID-19 Vaccine “Association of 2024–2025 Covid-19 Vaccine with Covid-19 Outcomes in U.S. Veterans” Katelyn Jetalina: Updated 2025 fall vaccine guide Learn more about the MBA for Executives program at Yale SOM. Email Howie and Harlan comments or questions.

Visit our Sponsors and check out EXCLUSIVE OTP Savings! www.OTPLinks.com www.tryshed.com (use code OTP25 to save 25%) Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Remote-podcast fra Bali til Kongens København, et WhatsApp-land – alle ved, hvad det indebærer, Bali-korrespondenten er på ferie; tag på den samme ferie i ti år og fortsæt som dine forældre, Værns lydhealingsfirma er lige på trapperne, Pakistan og Taliban er i totterne på hinanden, Israelske gidsler og palæstinensiske krigsfanger udleveres, Trump og Air Force One lander i Israel og besøger Netanyahu, Omikronen fra 2020 sidder stadig i svælget på Esben Bjerre fra Silkeborg, Nye bivirkninger på Wegovy'en, Turen går til Spanien – med tidsmaskinen, alt for mange hensyn til de møgdyr, infil/exfil på Bad Bunny-koncert, selv i de mindste flækker i tredjeverdenslande er der produkter fra Nestlé, fødevareindustrien er slyngler på indpakningen, #UgensFilm med Leonardo, indslaget: “Husk proportionerne.” Fingrene væk fra Natos artikel fem – i form af Planet-Nusa-damerne – og et virkelighedsfjernt adgang til et sponsorat-regelsæt og rasende energi på radio-tv-nævnet. Få 30 dages gratis prøveperiode (kan kun benyttes af nye Podimo-abonnenter)- http://podimo.dk/hgdg (99 kroner herefter)Værter: Esben Bjerre & Peter FalktoftRedigering: PodAmokKlip: PodAmokMusik: Her Går Det GodtInstagram:@hergaardetgodt@Peterfalktoft@Esbenbjerre

As demand for GLP-1 drugs like Ozempic and Wegovy soars, a parallel market for compounded versions has emerged — one that's largely unregulated and increasingly risky. This episode examines how gaps in oversight, aggressive marketing, and blurred lines between compounding and manufacturing expose patients to safety concerns and strain the health system. We explore why compounded GLP-1s are more than a niche issue, highlighting how they fit a recurring pattern where regulation lags behind fast-moving markets.

In today's episode, I'm diving into everything you need to know about Zepbound (tirzepatide) — the newest obesity medication now available in Canada. I'll explain how this dual GIP/GLP-1 agonist works, how it's different from semaglutide (Ozempic/Wegovy), and who it may be helpful for.We'll talk about expected weight loss results, side effects, cost, and access, as well as one really important topic: how to protect your muscle and bone health while on these medications. Rapid weight loss can come with downsides — and I'll share what you can do to make sure your journey is sustainable and healthy.In this episode, I cover: → How tirzepatide works and what makes it unique → Expected weight loss and blood sugar improvements → Common side effects and safety considerations → Tirzepatide vs. semaglutide — what's the difference? → Cost, access, and insurance coverage in Canada → Why protein and strength training are essential during weight lossAs always, this podcast is for educational purposes only and not a substitute for personalized medical advice. Please talk to your doctor before making any changes to your treatment plan.Come connect with me on Instagram @sashahighmd, and don't forget to subscribe so you never miss a Monday episode! Other episodes: 108. All About Wegovy97. All About Mounjaro53. All About Ozempic145. Which one is better, Ozempic, Wegovy or Mounjaro?

We're going there today.Ozempic, Wegovy, Mounjaro — the weight-loss drugs everyone's talking about.But here's what no one's saying: yes, these meds work… but at what cost?In this episode, Nikkiey Stott breaks down the truth about GLP-1 weight-loss drugs, the science behind how they actually work, and the reality of what happens when you stop taking them. She dives into the research on muscle loss, metabolism slowdown, and why relying on medication alone sets so many women up for the rebound cycle they've spent years trying to escape.This isn't about fear — it's about facts.You'll walk away understanding: • Why muscle is the single most important factor in fat loss after 40 • What studies really show about GLP-1s and metabolism • The right vs. wrong way to use weight-loss meds (if you choose to) • And the exact lifestyle framework that always wins — with or without a prescriptionIf you're tired of chasing shortcuts and ready to finally understand how to create sustainable results, this episode will change the way you see your body, your health, and your power.

In this episode, Ali speaks with Dr. James A. Simon, a leading OB-GYN and "Menopause Whisperer," about his pioneering work in sexual medicine and menopause care. Dr. Simon discusses the challenges and importance of addressing sexual health in gynecology, the evolution of hormone therapy, and the cultural barriers that often prevent open conversations about menopause and women's sexuality.The episode highlights the need for more holistic, individualized care for women, the impact of hormones on health and wellbeing, and the progress still needed in medical education and societal attitudes. Listeners will come away with a deeper understanding of menopause, hormone therapy, and the value of compassionate, open dialogue about women's health and aging.Topics also include how aging has changed over generations, why people got scared of Hormone Replacement Therapy, the prevalence and benefits of testosterone in women, the politics of hysterectomies, how Viagra was happened upon, and how GLP-1s work. FOR MORE ALI MEZEY:ALI - WebsiteALI - LinkTreeFOR MORE JAMES:IntimMedicine Website: https://intimmedicine.com/YouTube: https://www.youtube.com/@intimmedicinespecialists5815/videosFacebook: https://www.facebook.com/IntimMedicineRestore Yourself: A Woman's Guide to Reviving Her Sexual Desire and Passion for LifeBook by Dr. James A. Simon.JAMES BIO:James A. Simon, MD, CCD, MSCP, IF, FACOGDr. James A. Simon is a board-certified Ob/Gyn, and reproductive endocrinologist. He is Clinical Professor of Obstetrics and Gynecology at The George Washington University School of Medicine in Washington, DC. Dr. Simon also holds certifications as an AASECT-Certified Sexuality Counsellor, an ISCD-Certified Clinical Bone Densitometrist, and a Menopause Society-Certified menopause specialist. He has an active private practice, IntimMedicine Specialists® in Washington, DC focused on complicated gynecology, sexual medicine for both men and women, and menopause. Dr. Simon has received numerous awards including: “Top Washington Physicians,” “America's Top Obstetricians and Gynecologists,” “Super Doctors of Washington DC-Baltimore-Northern Virginia,” and “The Best Doctors in America.” He is the only physician to serve as President of both The Menopause Society and the International Society for the Study of Women's Sexual Health. Nicknamed “The Menopause Whisperer,” by Washingtonian Magazine, Dr. Simon is an established researcher and author--completing more than 450 research trials, and more than 800 published articles, abstracts, chapters, and the paperback book: Restore Yourself: A Woman's Guide to Reviving Her Sexual Desire and Passion for Life. Dr. Simon loves riding the best rollercoasters in the world, collecting fountain pens and wristwatches, and freshwater fishing. He is a five-time Master Angler of Canada.hiker, dog trainer, and lover of nature.OTHER RESOURCES, LINKS AND INSPIRATIONS: ASECT (American Association of Sexuality Educators, Counselors and Therapists)A professional organization for sexuality educators, counselors, and therapists.ISCD (International Society for Clinical Densitometry)Organization focused on bone density and skeletal health.Menopause SocietyFormerly known as the North American Menopause Society (NAMS), dedicated to promoting the health and quality of life of women through an understanding of menopause.International Society for the Study of Women's Sexual Health (ISSWSH)Multidisciplinary, academic, and scientific organization dedicated to women's sexual health.Washingtonian Magazine ArticleRegional magazine that dubbed Dr. Simon "The Menopause Whisperer."Sexual Health AllianceOrganization and conference for sexual health professionals.Women's Health Initiative Hormone StudiesLandmark studies on hormone therapy in women.Menopause MeetingsAnnual conferences for menopause specialists.PremarinEstrogen medication derived from pregnant mares' urine, historically used in hormone therapy.Viagra (Sildenafil)Medication for erectile dysfunction, originally developed for high blood pressure.GLP-1 Receptor AgonistsClass of injectable medications for diabetes and weight loss (e.g., Ozempic, Wegovy).Dr. Dympna RenshawSouth African psychiatrist and pioneer in sexual medicine, especially in the context of trauma and dysfunction.Halle Berry, Kate WinsletCelebrities mentioned for their advocacy and openness about menopause.Contraception Marches (late 1960s)Historical reference to activism for access to contraception.[From time to time, a word or phrase goes wonky. Please forgive my wandering wifi.]

In this special RxBenefits-sponsored episode of The ASHHRA Podcast, hosts Bo Brabo and Luke Carignan explore the dynamic pharmacy benefits landscape with experts Sarah Hearn and Wes Hill (Director of Compliance & Legal Operations). Amid the busiest legislative season yet—over 1,500 bills—they discuss PBM reforms, ERISA challenges, compounding alternatives for GLP-1 drugs like Ozempic, 340B pricing, and emerging lawsuits. Gain insights on transparency, cost savings, and compliance for healthcare HR pros navigating employee benefits.Key takeaways for healthcare HR leaders:Legislative Surge: 1,500+ state bills target PBMs, carriers, and more; expect increased reporting burdens but better data for informed decisions.ERISA Erosion Risks: States challenge federal uniformity—multi-state plans face conflicting laws; monitor for compliance headaches.Positive Reforms: New mandates empower plan sponsors with PBM data; leverage 340B and coupons to cut costs (e.g., Wegovy from $1,000 to $100/month).Compounding & Innovation: Affordable GLP-1 alternatives via telehealth, but ensure safety and avoid controlled substance pitfalls.Lawsuits to Watch: Oklahoma ERISA win; Arkansas PBM permit ban challenges interstate commerce—outcomes could reshape operations.Action Steps: Demand vendor transparency; align with ERISA; educate teams on benefits to prevent misuse and optimize savings.Essential listening for HR managing rising pharmacy costs and regulations. Spark curiosity—reach out to RxBenefits for guidance!From Our Sponsors...Optimize Pharmacy Benefits with RxBenefitsElevate your employee benefits while managing costs. Did you know hospital employees fill 25% more prescriptions annually than other industries? Ensure cost-effective, high-quality pharmacy plans by leveraging your hospital's own pharmacies. Discover smarter strategies with RxBenefits.Learn More here - https://rxbene.fit/3ZaurZNStreamline HR Compliance with oneBADGEhealthcareSimplify screening, credentialing, and compliance for healthcare HR. oneBADGEhealthcare from ISB Global offers a tailored solution to keep your workforce compliant and efficient. Built for healthcare leaders, it's your all-in-one compliance tool.Get Started here - https://isbglobalservices.com/onebadgeunitedstates/ashhra/ Support the show

Hoy quiero hablarte de dos medicamentos que se han vuelto cada vez más populares: Mounjaro y Rybelsus. Probablemente has escuchado que ayudan a bajar de peso, que son ‘la nueva revolución', o incluso que reemplazarán a Ozempic… pero, ¿qué hay detrás de todo esto? En este episodio te voy a explicar cómo funcionan, en qué se parecen y en qué se diferencian, y lo más importante: qué papel realmente tienen dentro de un cambio de hábitos saludables. Canal de Youtube Visita nuestra página web:  Hábitos Inteligentes ¡Síguenos en instagram!  Agenda tu cita por WhastApp     

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.A new survey from CRB shows that most life sciences companies, particularly smaller biotechs, are not planning new investments in response to tariffs. The majority of manufacturing initiatives in the U.S. made in response to tariffs are coming from big pharma companies. Sky Bioscience's CB1 inhibitor, Nimacimab, showed promising weight-loss results when combined with Wegovy despite falling short of expectations in a mid-stage obesity trial. Amgen will offer its lipid-lowering drug Repatha directly to patients at a 60% discount. Biospace has honored 40 under 40 leaders in biopharma whose achievements reflect the industry's grit and impact. Pfizer beat out two other suitors for a takeover of Metsera. Maplight seeks a $227 million IPO for its neuropsych portfolio.AMT designation is taking its first steps amid uncertain benefits. Pharming's restructuring triggers a 20% reduction in its workforce. Experts are forging new paths to address scalability, cost, and other barriers surrounding cell therapy production.The CDC has adopted ACIP recommendations on chickenpox and COVID-19 vaccines. Stay tuned for upcoming events such as webinars on mRNA medicine, biopharma deregulation, and transforming digital sequences into mRNA.Various job opportunities in the life sciences industry include positions at Sonothera, Eli Lilly and Company, and Amgen.Support the show

Episode 1809 - brought to you by our incredible sponsors: True Classic- TrueClassic.com/HARDFACTOR to try them out for yourself. Hydrow- Go to Hydrow.com and use code HARDFACTOR to save up to $450 off your Hydrow Pro Rower! DaftKings- Download the DraftKings Casino app, sign up with code HARDFACTOR, and spin your favorite slots! The Crown is Yours - Gambling problem? Call one eight hundred GAMBLER Lucy- Let's level up your nicotine routine with Lucy.  Go to ⁠⁠Lucy.co/HARDFACTOR⁠⁠ and use promo code (HARDFACTOR) to get 20% off your first order. Must be of age-verified. Better Help - Our listeners get 10% off their first month of online therapy at BetterHelp dot com slash HARDFACTOR Timestamps: 00:00:00 Timestamps 00:04:10 Happy birthday to Wes' Mom 00:05:50 Costco to begin selling Ozempic and Wegovy for half off 00:18:15 Scientists release a report that humans have a lot of alien DNA thanks to abductions 00:24:15 Good old-fashioned cigarette smuggling drone operation in Lithuania  00:28:20 Recall on Canadian thc pouch products Chillows for having way more mgs than advertised 00:32:15 20k bounty placed on man accused of cutting off sea lion's head in front of daughter  Thank you for listening!! If you're still reading, join our community at patreon.com/hardfactor to get access to bonus podcasts, discord chat, and much more... but Most importantly: HAGFD!! Learn more about your ad choices. Visit megaphone.fm/adchoices

 Headlines: – Welcome to Mo News (02:00) – Judge Declines to Stop Guard Troops From Deploying in Illinois, for Now (04:00) – Bari Weiss Named Editor In Chief Of CBS News (12:45) – Day Seven Of The Government Shutdown (19:15) – White House Avoids Setting Deadline For Gaza Talks, But Says It Wants Deal ‘Quickly' (23:50) – Hostage Families Urge Nobel Committee To Give Trump Peace Prize (26:450 – Survey: Most Jewish Americans Say Antisemitism Now Part Of Daily Life (27:15) – Supreme Court Rejects Appeal From Ghislaine Maxwell (28:30) – Costco to Sell Popular Weight-Loss Drugs Ozempic and Wegovy (30:50) – Online Holiday Spending Growth Set To Slow To 5.3% As Shoppers Seek Discounts (32:00) – On This Day In History (33:10) Thanks To Our Sponsors:  – ⁠LMNT⁠ - Free Sample Pack with any LMNT drink mix purchase –⁠ Industrious⁠ - Coworking office. 50% off day pass | Promo Code: MONEWS50 – Incogni - 60% off an annual plan| Promo Code: MONEWS – Leesa – 25% off mattress, plus extra $50 off | Promo Code: MONEWS – Factor Meals – 50% your first box plus free shipping | Promo Code: monews50off – Monarch Money - 50% off your first year | Promo Code: MONEWS

SUPPORT OUR WORK: OTPLinks.com

Group Chat News is back with the hottest stories of the week including the government shutdown, Diddy gets sentenced to 4 years in prison, Costco will now sell Ozempic and Wegovy at a discounted price, and Bronny may be the next golf superstar. 

GLP-1s — Ozempic, Wegovy, Mounjaro — they are everywhere right now. Your group chat's talking about them, they're all over TikTok, and maybe even your doctor's mentioned them. You've probably heard that they help with weight loss or that they ‘quiet food noise' — but what's really going on inside your body when you're on these meds? And more importantly what should we, as women, actually know when it comes to our hormones, metabolism, and long-term health? Because let's be real our bodies are not one-size-fits-all, and wellness isn't just about shrinking down a size. So today, we're getting into the real talk: what GLP-1s do, the benefits, the downsides, and how nutrition still plays a major role — whether you're on them, thinking about them, or just trying to make sense of all the hype. Listen up!  The Flourish Heights Podcast was made for women, by women. To be empowered in health starts with a true connection with your body. Join Valerie Agyeman, Women's Health Dietitian as she breaks through topics surrounding periods, women's nutrition, body awareness, and self-care.  Stay Connected: A research review on GLP-1's: https://pmc.ncbi.nlm.nih.gov/articles/PMC10972401/ Follow us on social media: Instagram: @flourishheights / @valerieagyeman / Women's Health Hub: @flourishvulva Is there a topic you'd like covered on the podcast? Submit it to hello@flourishheights.com Say hello! Email us at hello@flourishheights.com Subscribe to our quarterly newsletters: Flourish Heights Newsletter Visit our website: www.flourishheights.com Want to support this podcast? Leave a rating, write a review and share! Thank you!

Resources for the Community:___________________________________________________________________https://linktr.ee/theplussidezpodcast Ro - Telehealth for GLP1 weight management https://ro.co/weight-loss/?utm_source=plussidez&utm_medium=partnership&utm_campaign=comms_yt&utm_content=45497&utm_term=55Find Your US Representatives https://www.usa.gov/elected-officials ______________________________________________________________________This isn't medical advice — always talk to your doctor before making any health decisions.Join us for an eye-opening conversation with Dr. Komal Patil-Sisodia, MD, a board-certified endocrinologist and obesity medicine specialist, as we uncover why healthcare access is so broken for patients seeking GLP-1 treatments and women's health support. From insurance denials to systemic inequities, Dr. Patil-Sisodia breaks down where the system fails—and how it could change for the better. We're also joined by Sabina, founder of GLP Winner, who shares her personal journey with obesity and her mission to help others find reliable information and providers for GLP-1 medications like Ozempic, Wegovy, Mounjaro, and Zepbound.Community Guest: Sabina | https://www.glpwinner.com/ - Helps compare GLP-1 provider options with transparent pricing, sourcing, and reviews.https://www.tiktok.com/@lawliepophttps://www.instagram.com/lawliepops/https://www.youtube.com/@lawliepophttps://x.com/lawliepopDoctor Guest: Dr Komal Patil-Sisodiahttps://www.instagram.com/drpatilsisodia?igsh=MWZyaHY2Mm1naGVwOA%3D%3D&utm_source=qrhttps://www.tiktok.com/@drpatilsisodia?_t=ZT-8zzn5gQRlvy&_r=1https://www.resetrecharge.com/https://www.eastsidemm.com/_______________________________________________________________Send us Fan Mail! GetClaimable.com/PlusSideZ to appeal your GLP-1 Insurance Denails and use code PlusSideZ to save! Support the showKim Carlos, Executive Producer TikTok https://www.tiktok.com/@dmfkim?is_from_webapp=1&sender_device=pc Instagram https://www.instagram.com/dmfkimonmounjaro?igsh=aDF6dnlmbHBoYmJn&utm_source=qr Kat Carter, Associate Producer TikTok https://www.tiktok.com/@katcarter7?is_from_webapp=1&sender_device=pc Instagram https://www.instagram.com/mrskatcarter?utm_source=ig_web_button_share_sheet&igsh=ZDNlZDc0MzIxNw==

What does it really look like to set realistic expectations with weight loss medications like Zepbound and Wegovy?That's the focus of today's episode, and I'm joined by someone who knows this topic inside and out—Ana Reisdorf, a registered dietitian with over 15 years of experience. Ana is the founder of the GLP-1 Hub, where she provides resources, education, and support for people using GLP-1 medications. She also hosts a podcast dedicated to helping patients navigate the ups and downs of this journey.In our conversation, Ana shares why setting realistic expectations is so important—from understanding how dosing really works, to rethinking nutrition, and even reframing what progress looks like beyond the scale. She also points out common mistakes, like rushing to the highest dose too quickly or overly restricting food, and offers practical guidance on how to avoid them.We talk about:Why balanced nutrition is essential when taking weight loss medicationsWhy the right dose isn't always the highestManaging expectations and comparisons with weight loss medicationsRethinking “responders” and “non-responders” in weight loss medicationsProtein obsession vs. balanced nutritionThe role of fiber and balance in GLP-1 nutritionWhy GLP-1 medications aren't a shortcut—and how to use them effectivelyHow obesity and malnutrition can coexistAt the heart of this conversation is Ana's message that success with GLP-1s isn't just about losing weight—it's about improving health, nourishing the body, and creating a sustainable approach.Catch the full episode for more of Ana's insights and practical advice that can guide your own journey.Connect with Ana:Website: GLP-1 HubFacebook: GLP-1Hub Instagram: glp1hubYoutube:GLP-1 HubConnect with me:Instagram: doctorfrancavillaFacebook: Help Your Patients Lose Weight with Dr. FrancavillaWebsite: Dr. Francavilla ShowYoutube: The Doctor Francavilla ShowGLP Strong: glpstrong.com

Are your food cravings stronger in perimenopause or menopause? You're not imagining it! Hormones like GLP-1 play a big role in appetite, metabolism, and even mood. In this episode, I sit down with Sarah Kennedy, Founder and CEO of Calocurb, to talk about how a natural GLP-1 activator made from a completely natural extract helps reset satiety hormones, reduce cravings, and support healthy weight management…without drugs or injections. We cover: What GLP-1 is and how it changes during perimenopause Why Ozempic and Wegovy are everywhere,  and what's happening in New Zealand How a completely natural extract, activates GLP-1 naturally The difference between synthetic drugs and natural GLP-1 activators Sarah Kennedy is the Founder and CEO of Calocurb Ltd, the company behind a revolutionary natural GLP-1 activator that helps manage appetite and cravings. Calocurb was born from over 15 years and $30 million of New Zealand Government–backed science and is now sold in five international markets. Before Calocurb, Sarah was a senior executive at Fonterra, serving as Vice President of International Farming in China, Managing Director of Dairy Nutrition, and Managing Director of RD1-Fonterra's chain of rural retail stores. Earlier, she led Healtheries/Vitaco NZ Ltd, tripling company revenue and steering the merger that created Australasia's third-largest health and wellbeing brand. A veterinarian by training, Sarah also holds an MIT Sloan Fellowship in Global Leadership and Innovation, and has served on multiple boards spanning government, philanthropic, and private sectors.   10% off with code ZORA at https://www.calocurb.com/zora 30 Day money back guarantee! Contact Sarah Kennedy Email: hello@calocurb.com  Website: https://calocurb.com Instagram: https://www.instagram.com/calocurb /  Facebook: https://www.facebook.com/calocurbGLOBAL   Give thanks to our sponsors: Try Vitali skincare. 20% off with code ZORA here https://vitaliskincare.com Get Primeadine spermidine by Oxford Healthspan. 15% discount with code ZORA ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠here⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Get Mitopure Urolithin A by Timeline. 20% discount with code ZORA at https://timeline.com/zora Try Suji to improve muscle 10% off with code ZORA at TrySuji.com https://trysuji.com Try OneSkin skincare with code ZORA for 15% off  Join ⁠⁠⁠Biohacking Menopause⁠⁠⁠ before November 1, 2025 to win a Theranordic's Daily Healthy Fiber and Optimized Enzymes. Or 10% off at thearnordic.com with code ZORA   Join the Hack My Age community on: YouTube: https://youtube.com/@hackmyage Facebook Page: ⁠⁠⁠⁠⁠@⁠Hack My Age⁠     Facebook Group: ⁠⁠⁠⁠⁠⁠@⁠Biohacking Menopause⁠⁠⁠⁠⁠⁠ ⁠  https://www.facebook.com/groups/biohackingwomen50 Private Women's Only Support Group: https://hackmyage.com/biohacking-menopause-membership/ Instagram: ⁠⁠⁠⁠⁠@⁠HackMyAge⁠    Website: ⁠⁠⁠⁠⁠⁠HackMyAge.com⁠   

Leave Health Bite a Feedback.Click This Link.Your physical hunger is actually trying to tell you something deeper about your emotional and spiritual needs—and science proves it.Even with powerful appetite-suppressing medications like GLP-1s (Ozempic, Wegovy, Mounjaro), Dr. Adrienne Youdim reveals why emotional hunger still demands to be heard—and why that's actually a good thing for your wellbeing.In this science-backed episode, discover how stress, loneliness, and unmet needs literally trigger the same hunger hormones as fasting, and why appetite suppression doesn't equal emotional regulation.What You'll Learn:The surprising science of how emotional hunger triggers real biological hunger hormones (ghrelin, leptin, GLP-1)Why stress literally makes your hunger hormones spike—it's not just willpower or weaknessHow to identify what you're really hungry for: belonging, respite, validation, or connection"Appetite suppression does not equal emotional regulation. Emotional regulation requires its own attention because emotional eating is a form of reactivity—an automatic, habitual attempt to distract, soothe, or suppress some emotional or spiritual experience." - Dr. Adrienne YoudimCommon Hidden Hungers Explored:Hunger for Belonging: Loneliness and isolation driving you to the pantry instead of toward connectionHunger for Respite: Self-neglect and caretaking burnout manifesting as food cravingsHunger for Validation: High-achiever patterns that once served you now becoming destructiveThe Three-Part Framework for Emotional Hunger:Regulate: Break the reactivity cycle with pause practicesBefore: Immediate reactive response to emotional triggers—reaching for food, scrolling, overworkingAfter: Space between trigger and reaction, calmed nervous system, intentional choiceThe Tools: Deep breathing, body scans, nature walks, guided visualization, five-minute pauses before actingRestore: Build rituals that support emotional regulationBefore: Sporadic self-care, inconsistent coping mechanisms, reliance on reactive behaviorsAfter: Sustainable practices that consistently address emotional needsThe Rituals: Morning journaling, lunch walks, Sunday hikes, creative expression, structured eating and movement routinesReframe: Transform hunger from shame to signalBefore: Viewing emotional hunger as weakness, something to suppress or fixAfter: Understanding hunger as valuable information about unmet needs and misalignment with valuesThe Practice: Ask yourself: "What am I truly hungry for? What deep-seated need is my mind and body trying to attune me to? How can I live more aligned with my true north?"Why GLP-1 Users Have a Unique Opportunity:With the "food noise" quieted, you have the perfect window to build emotional awareness, develop coping skills, and retrain habitual pathways for lasting change beyond medication.Your emotional hunger is a signal—a call to action from your nervous system saying something critical needs a3 Ways that Dr. Adrienne Youdim Can Support You Subscribe to Dr. Adrienne's weekly newsletter https://www.dradrienneyoudim.com/newsletter Connect on Instagram : Follow @dradrienneyoudim for tips and inspiration on well-being and peak performance. Come back next week — Every episode of Health Bite explores the physical, emotional, and spiritual hungers that drive us, and delivers the essential “nutrients” you need to thrive.

GLP-1 medications like semaglutide and tirzepatide — better known as Ozempic, Wegovy, and Mounjaro — are transforming lives through significant weight loss. But along with the health benefits, many patients notice unexpected changes in their appearance: facial hollowing, skin laxity, and body deflation, often referred to as “Ozempic face.”   In this episode of The Aesthetic Doctor Podcast, Dr. Judith Borger explores how GLP-1s affect both the face and body — and what can be done to support our weight loss patients through these changes. Whether you're a a patient curious about safe, effective ways to restore balance and confidence or a provider looking to expand your toolkit of non-surgical treatment, this conversation offers practical strategies, safety insights, and compassionate guidance for navigating the GLP-1 journey.   Dr. Judith Borger Links: www.theaestheticdoctor.com www.instagram.com/doctorborger

GLP-1 drugs like Ozempic, Wegovy, and Mounjaro have become a cultural phenomenon, transforming appetite regulation and weight loss like nothing before. But with their rise comes a flood of imitators, from flashy “GLP-1 patches” to supplements like Calocurb, all promising the same results without the needles or prescriptions. In this episode, I break down what GLP-1 actually is, how these drugs work, and why they're so effective—not just for weight but also for cardiovascular outcomes. Then I take a closer look at the patches (spoiler: marketing magic, not science) and Calocurb's hops extract, which shows some early promise but lacks long-term data. If you're curious about food noise, appetite regulation, and how to separate science from sales tactics, this one's for you.Highlights:How GLP-1 drugs regulate appetite, cravings, and even food noiseWhy “GLP-1 patches” are all marketing and no scienceWhat Calocurb is, how it works, and the research behind itShort-term vs long-term evidence for appetite control Contact Mikki:https://mikkiwilliden.com/https://www.facebook.com/mikkiwillidennutritionhttps://www.instagram.com/mikkiwilliden/https://linktr.ee/mikkiwillidenSave 20% on all Nuzest Products WORLDWIDE with the code MIKKI at www.nuzest.co.nz, www.nuzest.com.au or www.nuzest.comCurranz supplement: MIKKI saves you 25% at www.curranz.co.nz or www.curranz.co.uk off your first order

Are compounded GLP-1 meds like semaglutide and tirzepatide a smart shortcut or a risky gamble? In this episode, Dr. Lisa breaks down the real risks, pros & cons, and expert recommendations around using compounded versions of Wegovy, Ozempic, and Zepbound. If you're curious about affordable options for weight loss medications, or wondering if compounded GLP-1s are safe, this episode is for you.Thanks for listening! If you'd like more support during your SMART weight loss & health focused journey, sign up for our FREE newsletter, or check out our program at: www.SmartWeightLossCoaching.com. We would love to help you reach your happy weight, and transform the way you talk to yourself about your body and the number on the scale. Negative thoughts about yourself don't have to take up so much brain space, and we'd be honored to help you reframe those thoughts. Also…We'd be grateful if you'd follow us and share our podcast with your friends & family. We're here to help you improve your health, live longer, healthier, and lose weight the SMART way! This episode was produced by The Podcast Teacher: www.ThePodcastTeacher.com.

This week @littlehannahsucks returns and we start off by discussing her professional ghost of a situation with her fella, posing the question:  Is love for someone with addiction bigger than the love you have for yourself?  @thechrisarmy discusses his journey with Fat Guy Medicine AKA Wegovy. We also discuss the Jimmy Kimmel thing, the weird D4VD case theories and how mmany people have big feelings. Plus where is Josh? You should definitely email  Joshuamann11@gmail.com  and ask him... Please like and subscribe wherever you stream and follow us on YouTube @newbergpod  or watch the show there https://youtu.be/ilwhsGnRrio 

Dr. Fatima Cody Stanford, a leading specialist in obesity medicine and on GLP-1s joins Kelly to answer all of your most pressing questions about weight loss drugs (Ozempic, Wegovy, ZepBound), potential side effects and if it's possible to stop the meds and keep off the weight! She explains why GLP-1s don't work the same for every person, how to manage weight loss related hair loss, and if Ozempic face is a thing. Plus Dr. Stanford breakdowns if GLP-1 boosters are a gimmick. Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.com for information about our collection and use of personal data for advertising.

When did Hollywood get so good at cucking? Can hot guys be character actors? Who's your work wife? Would you drink a bucket of Wegovy? And is Shrek real? Plus: Paris Hilton, #MeSlurp, Smooching+ and the Shaquille O'Neal of hiding behind a tree... of braces. Also: Haaaaamburger.Further content:• "I Couldn't Get a Job and I Lost Everything"• "It Had to Be You"• Serena Williams Opens Up About Being on a GLP-1• Subscribe to "Casuals with Katie Nolan" Hosted on Acast. See acast.com/privacy for more information.

A.M. Edition for Sept. 18. The entertainment giant is pulling ‘Jimmy Kimmel Live!' after Kimmel accused ‘MAGA-land' figures of exploiting Kirk's death, sparking outrage from conservatives. Plus, the WSJ's Peter Loftus explains how weight-loss pills are going to upend the market, as a Novo Nordisk trial shows the pill is just as effective as its Wegovy shot. And, royalty, lavish dinners and tech CEOs: Britain turns on the charm offensive as Donald Trump's state visit to the United Kingdom continues. Caitlin McCabe hosts. Sign up for the WSJ's free What's News newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices